henhaobio
Sign in

bioRxivImmunologyPreprint

Tissue-resident FOLR2+ macrophages associate with tumor-infiltrating CD8+ T cells and with increased survival of breast cancer patients.

R. N. Ramos, Y. Missolo-Koussou, Y. Gerber-Ferder, C. Bromley, M. Bugatti, N. G. Nunez, J. Boari Tosello, W. Richer, J. Denizeau, C. Sedlik, P. Caudana, F. Kotsias, L. L. Niborski, S. Viel, M. Bohec, S. Lameiras, S. Baulande, L. Lesage, A. Nicolas, D. Meseure, A. Vincent-Salomon, F. Reyal, C.-A. Dutertre, F. Ginhoux, L. Vimeux, , J. Helft

PDFDOI

Abstract

Macrophage infiltration is a hallmark of solid cancers and overall macrophage infiltration is correlated with lower patient survival and resistance to therapy. However, tumor-associated macrophages are phenotypically and functionally heterogeneous. Specific tumor-associated macrophage subsets might be endowed with antagonistic role on cancer progression and on the development of anti-tumor immunity. For instance, monocyte-derived TREM2+ tumor-associated macrophages have pro-tumorigenic and immunosuppressive functions. Here, we identify a discrete population of FOLR2+ tumor-associated macrophages positively correlating with patient survival in breast cancer. FOLR2+ macrophages are evolutionarily conserved across species and populate human and murine healthy mammary gland. Moreover, FOLR2+ macrophages co-localize with lymphoid aggregates containing CD8+ T cells in breast cancer and across ten other types of cancers. This study highlights antagonistic roles for tumor-associated macrophage subsets and paves the way for subset-specific therapeutic interventions in macrophages-based cancer therapies.

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.